{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:21Z","timestamp":1788153501733,"version":"build-2803163510"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor (ICI)-based induction therapy followed by definitive radiotherapy has emerged as a promising treatment strategy for patients with unresectable locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, many patients still experience disease progression and poor clinical outcomes. Although longitudinal circulating biomarkers may provide valuable prognostic information, their dynamic predictive value in this treatment setting remains largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled patients with unresectable LA-ESCC from a single medical center who received PD-1inhibitor-based induction therapy followed by definitive radiotherapy. In addition to baseline clinical and histopathological characteristics, 110 circulating biomarkers were serially collected throughout treatment to characterize longitudinal changes. A Bayesian joint model integrating baseline predictors with longitudinal biomarker trajectories was developed for dynamic survival prediction. Model discrimination and calibration were evaluated using time-dependent area under the receiver operating characteristic curve (AUCs) and Brier scores, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 376 patients were included, comprising a training cohort (n = 221) and an independent temporal test cohort (n = 155), yielding 328,104 longitudinal biomarker measurements. Following multistage variable selection procedure, latent class growth analysis identified distinct longitudinal trajectories of the albumin-to-globulin ratio (AGR) that are significantly associated with survival outcomes. Dynamic AGR value and trajectory emerged as the most informative longitudinal predictors among all candidate biomarkers. In the training cohort, the 12-, 24-, and 36-month AUCs were 0.85 (95% CI, 0.82-0.89), 0.92 (95% CI, 0.90-0.94), and 0.87 (95% CI, 0.84-0.91), respectively. In the test cohort, the corresponding 12- and 24-month AUCs were 0.80 (95% CI, 0.75-0.85) and 0.82 (95% CI, 0.78-0.86), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By integrating longitudinal AGR trajectories with baseline clinical information, the Bayesian joint model enables individualized, real-time prognostic updating and may facilitate dynamic risk stratification and risk-adapted management for patients with unresectable LA-ESCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1909638","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:10Z","timestamp":1788150490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic survival prediction using longitudinal AGR in unresectable locally advanced esophageal squamous cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Feng","family":"Du","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Xiao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jia","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","article-title":"Oesophageal cancer","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1802037","article-title":"Immunotherapy-based adjuvant treatment after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma according to pathological response","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1236","article-title":"Chemoradiotherapy and subsequent immunochemotherapy as conversion therapy in unresectable locally advanced esophageal squamous cell carcinoma: A phase II NEXUS-1 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103893","article-title":"Fraction dose escalation of split-course concurrent chemoradiotherapy following induction chemo-immunotherapy in unresectable locally advanced oesophageal squamous carcinoma in China (GASTO-10102): a single-centre phase 1 study","volume":"95","author":"Liu","year":"2026","journal-title":"EClinicalMedicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2026.04.026","article-title":"Consolidative camrelizumab following definitive concurrent chemoradiation therapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial","author":"Cheng","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i7.104959","article-title":"Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy","volume":"16","author":"Ma","year":"2025","journal-title":"World J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.1038\/s41467-024-51105-2","article-title":"Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70010","article-title":"In-depth analysis of the necessity and optimization strategies for adjuvant radiotherapy following neoadjuvant immunotherapy in the new era of esophageal cancer treatment","volume":"4","author":"Liu","year":"2025","journal-title":"Cancer Innov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-023-01839-2","article-title":"Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma","volume":"22","author":"An","year":"2023","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0973","article-title":"Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques","volume":"3","author":"Leeman","year":"2017","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216440","article-title":"The AEG-1-USP10-PARP1 axis confers radioresistance in esophageal squamous cell carcinoma via facilitating homologous recombination-dependent DNA damage repair","volume":"577","author":"Zhao","year":"2023","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S531145","article-title":"Dual targeting of inflammatory and immune checkpoint pathways to overcome radiotherapy resistance in esophageal squamous cell carcinoma","volume":"18","author":"Qu","year":"2025","journal-title":"J Inflammation Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1016\/j.cell.2025.10.020","article-title":"Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction","volume":"188","author":"Black","year":"2025","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103706","article-title":"Trajectories of perioperative serum tumor markers and colorectal cancer outcomes: A retrospective, multicenter longitudinal cohort study","volume":"74","author":"Li","year":"2021","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12916-023-02773-2","article-title":"Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2591219","article-title":"Albumin-globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients","volume":"57","author":"He","year":"2025","journal-title":"Ann Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00345-024-05148-1","article-title":"Preoperative blood-based nutritional biomarkers as significant prognostic factors after intravesical BCG therapy in patients with non-muscle-invasive bladder cancer","volume":"42","author":"Ye","year":"2024","journal-title":"World J Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12885-023-10809-2","article-title":"Effects of preoperative albumin-to-globulin ratio on overall survival and quality of life in esophageal cell squamous carcinoma patients: a prospective cohort study","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7150\/jca.19062","article-title":"Low preoperative albumin-to-globulin ratio predict poor survival and negatively correlated with fibrinogen in resectable esophageal squamous cell carcinoma","volume":"8","author":"Li","year":"2017","journal-title":"J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41512-020-00078-z","article-title":"Harnessing repeated measurements of predictor variables for clinical risk prediction: a review of existing methods","volume":"4","author":"Bull","year":"2020","journal-title":"Diagn Progn Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocx030","article-title":"Calibration drift in regression and machine learning models for acute kidney injury","volume":"24","author":"Davis","year":"2017","journal-title":"J Am Med Inform Assoc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201600238","article-title":"Dynamic predictions with time-dependent covariates in survival analysis using joint modeling and landmarking","volume":"59","author":"Rizopoulos","year":"2017","journal-title":"Biom J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033965","article-title":"Moving beyond the Cox proportional hazards model in survival data analysis: a cervical cancer study","volume":"10","author":"Li","year":"2020","journal-title":"BMJ Open"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3402\/ejpt.v6.27514","article-title":"Latent trajectory studies: the basics, how to interpret the results, and what to report","volume":"6","author":"van de Schoot","year":"2015","journal-title":"Eur J Psychotraumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fdata.2022.812725","article-title":"Bayesian joint modeling of multivariate longitudinal and survival data with an application to diabetes study","volume":"5","author":"Huang","year":"2022","journal-title":"Front Big Data"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1186\/s12885-025-15165-x","article-title":"The prognostic role of inflammation-based hematologic markers in stage I-III colorectal cancer: a retrospective analysis","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11517","DOI":"10.1038\/s41598-025-96592-5","article-title":"Preoperative pan-immuno-inflammatory values and albumin-to-globulin ratio predict the prognosis of stage I-III colorectal cancer","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-55879-x","article-title":"The predictive value of systemic inflammation response index and albumin-to-globulin ratio for prognosis in non-small cell lung cancer","volume":"16","author":"Xu","year":"2026","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/atm-2025-1-181","article-title":"Perioperative circulating tumor DNA profiling for recurrence risk in esophageal squamous cell carcinoma: moving toward a biology-driven surveillance model","volume":"14","author":"Klacking","year":"2026","journal-title":"Ann Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41698-025-00809-9","article-title":"Longitudinal investigation of albumin-to-globulin ratio for human cancers demonstrates benefit in postoperative serial remeasurement","volume":"9","author":"Li","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71714","article-title":"Clinical implications of nutritional intake in patients with esophageal squamous cell carcinoma receiving chemoradiotherapy and neoadjuvant chemotherapy","volume":"15","author":"Tamai","year":"2026","journal-title":"Cancer Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.14084","article-title":"The impact of worsening nutritional status in neoadjuvant chemotherapy on postoperative outcomes in esophageal cancer","volume":"39","author":"Hasegawa","year":"2025","journal-title":"In Vivo"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106922","article-title":"Association of comprehensive inflammatory-metabolic status and perioperative outcomes in gastric cancer: insights from four randomized controlled trials","volume":"11","author":"Zhang","year":"2026","journal-title":"ESMO Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2483656","article-title":"Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis","volume":"17","author":"Vitale","year":"2025","journal-title":"Immunotherapy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu16010001","article-title":"Effects of malnutrition on the immune system and infection and the role of nutritional strategies regarding improvements in children's health status: a literature review","volume":"16","author":"Morales","year":"2023","journal-title":"Nutrients"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.06.039","article-title":"Targeting inflammatory pathways for tumor radiosensitization","volume":"80","author":"Deorukhkar","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1038\/s41467-022-35096-6","article-title":"Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer","volume":"13","author":"Sui","year":"2022","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1909638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:11Z","timestamp":1788150491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1909638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2026.1909638"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1909638","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1909638"}}